Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics

Company files for an injunction requiring FDA to announce whether Ranbaxy's atorvastatin ANDA is ineligible for 180-day marketing exclusivity, a determination that could clear the path for approval of other applications starting June 28.